Previous studies reported that HHLA2 was widely expressed in patients with PD‐L1‐negative NSCLC, intrahepatic cholangiocarcinoma, and osteosarcoma, suggesting that HHLA2 might be a promising immunotherapy target.10, 38, 39. The gene discussed is HHLA2; the disease is intrahepatic cholangiocarcinoma.